CRISPR Cas9 Genome Editing in Germlines

Slides:



Advertisements
Similar presentations
Lecture 45 Prof Duncan Shaw. Applications - finding genes Currently much interest in medical research, in finding the genes causing disease Sometimes.
Advertisements

CHAPTER 15 THE CHROMOSOMAL BASIS OF INHERITANCE Copyright © 2002 Pearson Education, Inc., publishing as Benjamin Cummings Section B: Sex Chromosomes 1.The.
Unit 4 Genetics Ch. 14 The Human Genome.
Genetic Engineering: Some Basic Concepts. DNA: The Information Carrier.
“CRISPR genome editing” Precise gene regulation/modification using the simple CRISPR/Cas9 system Thank you. Nucleeases will be used as a new tool that.
Seong-Eui Hong. Background
DNA Chips Attach DNA to tiny spots on glass slides (i.e., chip). Hybridize fluorescently-labeled DNA probes to chip. Detect hybridization to different.
Gene editing in embryos and germ line
Lecture-7 Genome editing CRISPR
Genome Editing Katie Plummer.
Date:01 December 2015 Time:6:30 – 9:30 pm Location:Emory University Presentation Room 308 Speakers:Dr. John Richardson National DMD Assoc. President Got.
Gene Therapy. What is Gene Therapy? Gene Therapy is the insertion of genes into an individual’s cells and tissues to treat a disease. Gene Therapy is.
What is muscular dystrophy? The muscular dystrophies (MD) are a group of genetic diseases characterized by progressive weakness and degeneration of the.
Gunn Abilities United Club. Muscular Dystrophy February 2014.
Gene Therapy Biology 11: Section 6.5. Learning Goals Students will describe gene therapy Students will describe the process of gene insertion.
Genetics and its relation to neuromuscular diseases
What do we need to know to become stem cell literate?
Genome editing to breed better plants
Molecular Therapy - Nucleic Acids
CRISPR is cheap, easy to do, and powerful… is it also dangerous?
Institute of Health and Biomedical Innovation
Molecular Therapy - Nucleic Acids
What is ... Gene Therapy?.
CRISPR-Cas9 in development and genetic disease
Duchenne muscular dystrophy (DMD)
Genome Editing and Gene Drive at UCI
Chapters 19 - Genetic Analysis of Development:
Peter John M.Phil, PhD Atta-ur-Rahman School of Applied Biosciences (ASAB) National University of Sciences & Technology (NUST)
February 11, 2016 Vic Myer, Chief Technology Officer.
Using molecular genetics for practical purposes
Different mode and types of inheritance
Must first identify the genome of the organism= all genes within the species
Mouse Models in Preclinical Studies for Pachyonychia Congenita
In vivo optimization of the tagging approach using the Act5C model locus and flow cytometry-based quantification of the Act5C-GFP tagging success. In vivo.
Purloined Mechanisms of Bacterial Immunity Can Cure Muscular Dystrophy
Gene Therapy Learning Goal: To explore gene therapy. Success Criteria:
Genome editing and CRISPR
Genomics for Regional Development
Molecular Therapy - Nucleic Acids
Correction of a Genetic Disease in Mouse via Use of CRISPR-Cas9
Chapters 19 - Genetic Analysis of Development:
Second International Summit on Human Genome Editing
The CRISPR/Cas9 system.1 Clustered regularly interspaced palindromic repeats (CRISPR) refers to sequences in the bacterial genome. The CRISPR/Cas9 system.1.
Gene Therapy Section 6.5.
Research Techniques Made Simple: The Application of CRISPR-Cas9 and Genome Editing in Investigative Dermatology  Joan Ramon Guitart, Jodi L. Johnson,
Fig. 1. Generation of the ΔEx50 mouse model.
CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles
Therapeutic editing of hepatocyte genome in vivo
USH2A Gene Editing Using the CRISPR System
The CRISPR/Cas9 system.1 Clustered regularly interspaced palindromic repeats (CRISPR) refers to sequences in the bacterial genome. The CRISPR/Cas9 system.1.
CRISPR: What is it? Biotech Ethics, Fall ‘18.
Andrew R. Bassett, Charlotte Tibbit, Chris P. Ponting, Ji-Long Liu 
by Valentino M. Gantz, and Ethan Bier
Volume 153, Issue 4, Pages (May 2013)
Current Progress in Therapeutic Gene Editing for Monogenic Diseases
Volume 10, Issue 4, Pages (April 2018)
Volume 153, Issue 4, Pages (May 2013)
Volume 16, Issue 4, Pages (April 2008)
Mouse Models in Preclinical Studies for Pachyonychia Congenita
Follistatin augments the power of myostatin inhibition discovered in mutant models J.D. Lowderman The Professional Program in Biotechnology, Texas A&M.
by Christopher E. Nelson, Chady H. Hakim, David G
Volume 26, Issue 6, Pages (June 2018)
Natalay Kouprina, Vladimir Larionov 
Volume 23, Issue 8, Pages (August 2015)
Fig. 1. Generation of the ΔEx50 mouse model.
Duchenne Muscular Dystrophy Models Show Their Age
Nuclease Target Site Selection for Maximizing On-target Activity and Minimizing Off- target Effects in Genome Editing  Ciaran M Lee, Thomas J Cradick,
Volume 10, Issue 5, Pages (November 2004)
CRISPR Craze to Transform Cardiac Biology
Fig. 3 Genome editing of the MSTN gene.
Presentation transcript:

CRISPR Cas9 Genome Editing in Germlines PBIO 4500 December 5, 2017 Sarah Disney

What is CRISPR Cas9? Discovered in E. coli CRISPR = Clustered Regularly Interspaced Short Palindromic Repeats An adaptive bacterial immune defense Cas9 = An endonuclease that uses a sgRNA to cleave a piece of DNA NHEJ = Non-homologous end joining HDR = homology directed repair Can be repaired using NHEJ or HDR. This can completely remove a dysfunctional gene and replace it with a healthy functioning version.

Prevention of muscular dystrophy in mice by CRISPR/Cas9–mediated editing of germline DNA Bassel-Duby et. Al The objective of this study was to correct the genetic defect in the Dmd gene of mice with muscular dystrophy through CRISPR/Cas9 mediated germline editing Did it work??? Bassel-Duby et. al. April 2014, Science mag.

Duchenne Muscular Dystrophy (DMD) X-linked disease 1 in 3,500 live male births Rare in girls Extremely debilitating Muscle weakness and degeneration Eventually fatal Begins to affect heart and respiratory muscles -men live into their 30s on average -begin to experience heart and respiratory problems in their teens

Methodology Developed DMD mice models Referred to as mdx Crossed mdx female and male to create mdx zygotes CRISPR/Cas9 was used to treat the germlines in vitro Zygotes were then reimplanted in a healthy mother This lead to mice with varying levels of mocaisism Referred to as mdx-C mice -We injected Cas9, sgRNA, and HDR template into mouse zygotes to correct the disease-causing gene mutation in the germ line (16, 17), a strategy that has the potential to correct the mutation in all cells of the body, including myogenic progenitors. Safety and efficacy of CRISPR/Cas9–based gene therapy was also evaluated. -Sequencing results revealed that CRISPR/Cas9–mediated germline editing produced genetically mosaic mdx-C mice displaying from 2 to 100% correction of the Dmd gene (Fig. 1E and fig. S2, B and C). A wide range of mosaicism occurs if CRISPR/Cas9–mediated repair occurs after the zygote stage, resulting in genomic editing in a subset of embryonic cells (18). All mouse progeny developed to adults without signs of tumor growth or other abnormal phenotypes. -We tested four different mouse groups for possible off-target effects of CRISPR/Cas9–mediated genome editing: (A) mdx mice without treatment (termed mdx), (B) CRISPR/Cas9–edited mdx mice (termed mdx+Cas9), (C) Wild-type control mice (C57BL6/C3H) without treatment (termed WT) and (D) CRISPR/Cas9–edited wild-type mice (termed WT+Cas9) (fig. S3A). Sequences of the target site (Dmd exon 23) and a total of 32 potential off-target (OT) sites in the mouse genome

Results Varying levels of mosaicism were effective Direct editing of satellite cells in vivo by the CRISPR/Cas9 system represents a potentially promising alternative approach to promote muscle repair in DMD. No significant negative effects were found in the treated mice -Mice with ~40% mosaicism are healthy -To analyze the effect of CRISPR/Cas9–mediated genomic editing on the development of muscular dystrophy, we performed histological analyses of four different muscle types [quadriceps, soleus (hindlimb muscle), diaphragm (respiratory muscle), and heart muscle] from wild-type mice, mdx mice, and three chosen mdx-C mice with different percentages of Dmd gene correction at 7 to 9 weeks of age. mdx muscle showed histopathologic hallmarks of muscular dystrophy, including variation in fiber diameter, centralized nuclei, degenerating fibers, necrotic fibers, and mineralized fibers, as well as interstitial fibrosis (Fig. 2 and figs. S4A and S5A). Immunohistochemistry showed no dystrophin expression in skeletal muscle or heart of mdx mice, whereas wild-type mice showed dystrophin expression in the subsarcolemmal region of the fibers and the heart (Fig. 2). Although mdx mice carry a stop mutation in the Dmd gene, we observed 0.2 to 0.6% revertant fibers, consistent with a previous report (24). mdx-C mice with 41% of the mdx alleles corrected by HDR (termed HDR-41%) or with 83% correction by in-frame NHEJ (termed NHEJ-83%) showed complete absence of the dystrophic muscle phenotype and restoration of dystrophin expression in the subsarcolemmal region of all myofibers (Fig. 2). Strikingly, correction of only 17% of the mutant Dmd alleles (termed HDR-17%) was sufficient to allow dystrophin expression in a majority of myofibers at a level of intensity comparable to that of wild-type mice, and the muscle exhibited fewer histopathologic hallmarks of muscular dystrophy than mdx muscle (fig. S4A). The substantially higher percentage (47 to 60%) of dystrophin-positive fibers associated with only 17% gene correction (fig. S6, A and B) suggests a selective advantage of the corrected skeletal muscle cells.

This data shows that there is no significant difference between CRISPR/Cas9 treated zygotes and untreated zygotes. -no difference in the frequency of indel mutations. -Deep sequencing of PCR products corresponding to Dmd exon 23 revealed high ratios of HDR and NHEJ-mediated genetic modification in groups B and D but not in control groups A and C

Ethics The ethics of human germline experimentation may be the most contentious conversation in science At the NAS Summit 2015, the NAS ruled that “it would be irresponsible to proceed with any clinical use of germline editing”. Specific safety and ethical criteria must be met before any use Additionally, the baby would have to be at imminent risk of severe genetic disease with no other viable options At what point is the use of a human embryo no longer justified? Where do we draw the line? Are we playing God?

References Long, C., McAnally, J. R., Shelton, J. M., Mireault, A. A., Bassel-Duby, R., & Olson, E. (2014). Prevention of muscular dystrophy in mice by CRISPR/Cas9– mediated editing of germline DNA. Science, 345(6201), 1184-1188. doi:10.1126/science.1254445 Sharma, A., & Scott, C. (2015). The ethics of publishing human germline research. Nature Biotechnology, 33(6).